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Figure 1. Total number of CD4+ Treg and Tem cells in the syngeneic vs. allogeneic recipients. Shown are total number of CD4+ Treg and Tem cells in the graft (day 0),
and at subsequent time points following AHSCT for syngeneic (syn) recipients, identical host recipient pairs; and allogeneic (allo) recipients, with minor antigen
mismatch between host and donor with resultant cGVHD induction. Day+14 is a time point early post AHSCT, while day +28 represents well-established cGVHD.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354S328higher than the number present in the graft, but distrib-
uted to target rather than non-target tissues. Target sites of
cGVHD (skin, gut and liver) had several fold greater num-
ber of Tem cells compared to controls both early and late in
disease. The number of Tem cells in target sites was
maintained as cGVHD progressed, and the Treg to Tem ratio
in target tissues was signiﬁcantly lower than that of the
controls at all times. Cell division of Tem and Treg cells was
high in the liver, and remained high for the Treg cells as
disease progressed. Meanwhile, Treg cells underwent
faster loss from the liver, likely due to cell death given that
the total number of Treg cells did not change. Our ﬁndings
shed light on in vivo behavior of Treg and Tem cells, T cell
subtypes critical to the biology of cGVHD. Furthermore, our
methodology will be translated to investigate in vivo T cell
kinetics in patients undergoing AHSCT as deuterated water
labeling is safe, not toxic and non-radioactive.475
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Ocular chronic GVHD (cGVHD) is one of the most bother-
some and common long-term complications after allogeneic
HCT. The 2005 NIH cGVHD Consensus Project provided
expert recommendations for diagnosis: dry, gritty, or painful
eyes, cicatricial conjunctivitis, keratoconjunctivitis sicca or
conﬂuent areas of punctate keratopathy in conjunction with
abnormally low Schirmer’s tear test. However these have not
been prospectively validated in patients. The goal of this
analysis was to identify predictive models for ocular cGVHD
diagnosis, disease activity and clinical correlates that could
be feasibly employed by transplant clinicians to assess out-
comes in clinical practice and therapeutic trials. Between2004 and 2013, 210 patients with moderate (n¼57) or severe
(n¼151) cGVHD were enrolled on the NIH/NCI cGVHD cross-
sectional observational study (NCT00092235). Median time
from cGVHD diagnosis to enrollment was 765 (20-6670)
days. Patient-reported outcomes (PROs) and transplant-
clinician-reported outcomes (ClinROs) were gathered:
Schirmer’s, NIH eye score (0-3), Lee cGVHD symptom scale
(dry eye, needs eye drops frequently, and difﬁculty seeing
clearly) (each 0-4) and chief eye symptom intensity scale (0-
10). Participants were examined by ophthalmologists expe-
rienced in diagnosing and treating ocular cGVHD (MBD, RJB),
who conﬁrmed the diagnosis and classiﬁed patients as active
vs. inactive. Univariate analyses and logistic models were
developed to examine the associations among ophthalmol-
ogist assessment, PRO and ClinRO measures. Based on
ophthalmology evaluation, 157 (75%) patients were diag-
nosed with ocular cGVHD; a majority (133/157; 85%) had
active disease. In a multivariable model, the NIH eye score (3
vs. 2 vs.1) (p<0.0001) and lower Schirmer’s (p<0.0001) were
signiﬁcant independent predictors of ocular cGVHD (sensi-
tivity 93.0%, speciﬁcity 92.2%). The Lee dry eye was the
strongest predictor of active ocular cGVHD (p<0.0001)
(sensitivity 68.5%, speciﬁcity 82.6%). The following risk fac-
tors for ocular cGVHD were identiﬁed: related donor
(p¼0.0029) and HLA matched (p¼0.0095) HCT. Oral cGVHD
was strongly associated with the diagnosis of ocular cGVHD
(p<0.0001). NIH eye score and Schirmer’s test are ClinRO
measures that are strongly predictive for diagnosis of ocular
cGVHD, while a single PRO item assessing dry eye symptom
bother had 82.6% speciﬁcity for ocular cGVHD activity. Re-
sults support the use of these items for routine screening and
ocular triage when providing long-term care to allogeneic
HCT survivors. Prospective studies are needed to determine if
a single PRO item assessing dry eye is sufﬁcient for use as a
trial outcome and to guide therapeutic decision-making in
clinical practice. We conﬁrm observations of others that
HLA-matched and related donor transplants are associated
with an increased risk of ocular cGVHD.476
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